
#Medchem @merckgroup former @bayerpharma interested in #cancer #kinaseinhibitors #degraders only personal views Reviewer @drughunter
Darmstadt, Germany
Joined November 2017
- Tweets923
- Following580
- Followers901
- Likes2.7K
Julien Lefranc retweeted

AACR@AACR28 Apr 2025
🇺🇸!
United StatesConnected via WebLocation may be affected by a proxy or VPN.Account-level information, not a live location or per-post device.
The three-part New Drugs on the Horizon Series at the AACR Annual Meeting 2025 wrapped up this morning. A total of 12 first-time disclosures were presented. #AACR25
Julien Lefranc retweeted
Molecule One-Pager: ARV-471 (vepdegestrant)
This molecule one-pager includes links to key presentations, publications, patents, preclinical and clinical PK data summaries, and more.
One-pager link: drughunters.com/3YoQR8v
Don't forget to follow the new account @ChemEurope !
We are switching Social Media accounts, and we will no longer post news from this account. Please follow us on @ChemEurope
Julien Lefranc retweeted
BMS-986365: A Next-Generation Oral AR Heterobifunctional Degrader for Drug-Resistant Prostate Cancer
This full case study details how BMS-986365 was engineered to have low intrinsic agonism and exert direct antagonism of WT AR and more!
Full Article: drughunters.com/4dIhx9d
Very nice to be back in Bristol for the CDT Summer Conference. A lot of great science presented by very talented PhD students ! Congratulations to @JonathanClayden, @VarinderAggar11 and @BCS_CDT
Julien Lefranc retweeted
If he could have dinner with a well-known historic figure, who would @AlexBismuto invite? @bismutolab @unibonn Find out on his #IntroducingAngewandte page xitter.cf/16467437/status/180278… onlinelibrary.wiley.com/doi/…
Light-Dependent Reactivity of Heavy Pnictogen Double Bonds (Alessandro Bismuto and co-workers) @bismutolab #openaccess onlinelibrary.wiley.com/doi/…
I keep being amazed by the work from @Rev_Medicine Here is a example from their last patent. This work is again pushing medicinal chemistry out of out comfort zone. 6 chiral centers, 1 atropisomer , a spiro and an aziridine ! Congratulations to @Les_Burnett and all the Team!
Dont miss that meeting !
There is still time to register for the Thematic meeting from @SCT_asso: Targeted Protein Degradation Gentilly @SanofiFR (Paris) with a fantastic program. You can click under the following link sct-asso.fr/tpdmeeting
Julien Lefranc retweeted
There is still time to register for the Thematic meeting from @SCT_asso: Targeted Protein Degradation Gentilly @SanofiFR (Paris) with a fantastic program. You can click under the following link sct-asso.fr/tpdmeeting
Check this symposium out if you haven't registered yet !
Replying to @Glaconde34
@iDikic2 (Max Planck Institut of Bio)
Dr. Manfred Koegl (Boehringer Ingelheim)
Dr. Samir Jegham (Sanofi)
Dr. Kirsten McAulay (Dundee University, CETP)
Prof. Anne-Sophie Voisin-Chiret (Caen university)
Check this out !!
Come and join us, what are you waiting for?! We have a fully funded PhD position @UniBonn on Sb- and Bi-luminescent compounds🧪. The deadline is April 24, interested candidate should send the application (cover letter and CV) to [email protected]
Julien Lefranc retweeted
Come and join us, what are you waiting for?! We have a fully funded PhD position @UniBonn on Sb- and Bi-luminescent compounds🧪. The deadline is April 24, interested candidate should send the application (cover letter and CV) to [email protected]
Julien Lefranc retweeted
🔥🔥“TPD one-day Thematic meeting” in Paris (SANOFI) May 30th 2024 @SCT_asso : register open bit.ly/4arCfZd
@DanNomura
Dr. M. Schroeder
@fmorreale_ester
Prof. N. Thomä
@iDikic2
Dr. M. Koegl
Dr. S. Jegham
Dr. K. McAulay
Prof. A.-S. Voisin-Chiret
Julien Lefranc retweeted
Molecules of the Month – Feb. 2024
Actelion revealed the discovery story of nivasorexant, a selective orexin-1 receptor antagonist, which completed a Ph. II clinical trial in binge-eating disorder.
Check out our other top molecules from Feb.!
Article | drughunters.com/3vbzEDY
Julien Lefranc retweeted
We have an open position for a postdoc in our Medicinal Chemistry & Drug Design department @merckgroup: If you are equally excited about chemistry automation and about applying synthetic chemistry to answer biological questions, check out this highly attractive opportunity!























